Emerging BCL2 Inhibitors

被引：0
|
作者：
Anderson, Mary Ann [1 ,2 ,3 ,4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic 3000, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia
[3] Walter & Eliza Hall Inst Med Res, Div Blood Cells & Blood Canc, Melbourne, Vic 3000, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic 3000, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
Venetoclax; small molecule inhibitors; apoptosis; BCL2; chronic lymphocytic leukemia; CHRONIC LYMPHOCYTIC-LEUKEMIA; PATIENTS PTS; LISAFTOCLAX APG-2575; ANTITUMOR-ACTIVITY; TARGETING BCL2; PHASE-I; VENETOCLAX; SAFETY; LYMPHOMA; MONOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S115 / S117
页数：3
相关论文
共 50 条
  • [21] OVEREXPRESSION OF BCL2 IN CML
    Sanchez Sosa, S.
    Lopez Rodriguez, J. F.
    Florido Ortega, Y.
    Stuckey, R.
    Gonzalez San Miguel, J. D.
    Tapia, M.
    Saez Perdomo, M. N.
    Gonzalez Perez, E.
    Segura Diaz, A.
    Molero Labarta, M. T.
    Bilbao Sieyro, C.
    Gomez Casares, M. T.
    HAEMATOLOGICA, 2019, 104 : 246 - 247
  • [22] Impact of BCL2 Mutations to BCL2 Protein Expression in B-Cell Lymphoma
    Baik, Jeeyeon
    Isgor, Irem
    Aypar, Umut
    Dogan, Ahmet
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1096 - S1097
  • [23] BCL2A1: the underdog in the BCL2 family
    Vogler, M.
    CELL DEATH AND DIFFERENTIATION, 2012, 19 (01): : 67 - 74
  • [24] BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
    Lui, Goldie Y. L.
    Shaw, Reid
    Schaub, Franz X.
    Stork, Isabella N.
    Gurley, Kay E.
    Bridgwater, Caroline
    Diaz, Robert L.
    Rosati, Rachele
    Swan, Hallie A.
    Ince, Tan A.
    Harding, Thomas C.
    Gadi, Vijayakrishna K.
    Goff, Barbara A.
    Kemp, Christopher J.
    Swisher, Elizabeth M.
    Grandori, Carla
    EBIOMEDICINE, 2020, 60
  • [25] Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
    Jing Zhang
    Xueying Lu
    Jianyong Li
    Yi Miao
    Biomarker Research, 10
  • [26] Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
    Bodur, C.
    Basaga, H.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (12) : 1804 - 1820
  • [27] BCL2A1: the underdog in the BCL2 family
    M Vogler
    Cell Death & Differentiation, 2012, 19 : 67 - 74
  • [28] Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
    Zhang, Jing
    Lu, Xueying
    Li, Jianyong
    Miao, Yi
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [29] Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
    Liu, Lin
    Mo, Wenbin
    Chen, Miao
    Qu, Yi
    Wang, Pingping
    Liang, Ying
    Yan, Xiaojing
    BMC CANCER, 2024, 24 (01)
  • [30] Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
    Hill, Brian T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 : 31 - 33
12345